ABT Stock Analysis: Buy, Sell, or Hold?
ABT - Abbott Laboratories
$109.30
3.21 (3.03%)
▲
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Apr 15, 2026
Get Alerted When ABT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called ABT this week
86% bullish • 1 bearish
86% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABT trading at deep discount. Market pricing in -7.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ABT trading at deep discount. Market pricing in -7.6% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$187.64
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$116.51
6.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABT is currently trading at $109.30, which is considered oversold relative to its 30-day fair value range of $112.72 to $127.89. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.0) compared to its historical average (21.6). Remarkably, the market is currently pricing in an annual earnings decline of 7.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ABT is in a downtrend. Immediate support is located at $105.27, while resistance sits at $123.49. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $136.32 (+28.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABT is in a downtrend. Immediate support is located at $105.27, while resistance sits at $123.49. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $136.32 (+28.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$112.72 -
$127.89
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 28.5% below Wall St target ($136.32)
Fair Price Analysis
30-Day Fair Range
$112.72 -
$127.89
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$105.27
Resistance Level
$123.49
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
17.03
Wall Street Target
$136.32
(+28.5%)
Revenue Growth (YoY)
4.4%
Earnings Growth (YoY)
-80.8%
Profit Margin
14.7%
Valuation Discount vs History
-7.6% cheaper
PE vs Historical
17.0 vs 21.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.6%
(market-implied from PE analysis)
1-Year Target
$98.03
(-8%)
2-Year Target
$90.58
(-15%)
3-Year Target
$83.69
(-21%)
3-Yr Target (if PE normalizes)
(PE: 17→22)
$106.14
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 9.8%)
$183.99
(+73%)
Base:
(SPY PE: 17.0, Growth: 9.8%)
$140.53
(+33%)
Bear:
(PE: 14.5, Growth: 9.8%)
$119.45
(+13%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 28.51 | Current EPS (TTM): $3.72
Bull Case
$195.32
(+79%)
Analyst growth 67.4%, PE expands to 31.4
Base Case
$177.57
(+63%)
Market implied 67.4%, PE stable at 28.5
Bear Case
$72.11
(-34%)
Severe decline -20.0%, PE contracts to 24.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.0 to 21.6
Stabilization Target:
$134.54
(+26.8%)
PE Expansion Potential:
+26.8%
Last updated: January 30, 2026 7:48 PM ET
Data refreshes hourly during market hours. Next update: 8:48 PM
Data refreshes hourly during market hours. Next update: 8:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Rick Larsen
BUY
2025-10-06
Michael T. McCaul
SELL
2025-08-21
Julie Johnson
SELL
2025-08-14
Featured in Portfolios
ABT is a key holding in these high-performance investment strategies.
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$124 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$110 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$374 | 54 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
Advanced ABT Option Strategies
Professional options setups generated by AI based on today's ABT price and gamma walls.
